Radioisotope of Actinium-225 (Ac-225)

The main articles are:

• Nuclear medicine
• Nuclear medicine in Russia

Manufacturers of Ac-225

SSC RF - FEI is one of the three producers of the radioactive isotope actinium-225 in the world and the only one in Russia (as of March 2023).

Specifications Ac-225

As of March 2023
Source: JSC "SSC RF - FEI"

As of March 2023
Illustration: JSC "SSC RF - FEI"

2023

Russia has significantly increased the production of radioisotope, which is used for the treatment of inoperable forms of cancer

The State Scientific Center of the Russian Federation - the A.I. Leipunsky Institute of Physics and Energy (part of the scientific division of Rosatom State Corporation) significantly increased the production of actinium-225 (Ac-225) due to the optimization of the production process. Representatives of SSC RF - FEI JSC spoke about this at an international conference on nuclear medicine in Cape Town of the Republic of South Africa, according to a statement on the institute's website dated March 15, 2023.

As the specialists of the State Research Center of the Russian Federation - FEI explained, this result was achieved, first of all, thanks to the update of the Ac-225 allocation scheme in the Th-229/Ac-225 generator system, improvement of quality control in the production of alpha emitters, as well as through the introduction of a quality management system at the institute in the production of radioisotope products in accordance with the requirements of ISO 9001 standards.

Specialists of the State Research Center of the Russian Federation - FEI shared successful experience in optimizing production processes, which made it possible to significantly increase the amount of actinium production
Photo: JSC "State Research Center of the Russian Federation - FEI"

The conference participants also discussed the results of preclinical and clinical studies of radiopharmaceuticals based on alpha emitters (alpha-emitting radionuclides that allow destroying tumor cells, maximally preserving healthy tissues), the statuses of projects for the development of alpha emitters, questions of determining the absorbed dose both in the tumor and in other organs, as well as issues of legislative regulation of the use of alpha emitters in nuclear medicine.

"The exchange of accumulated experience at the conference provided significant assistance to specialists working in the field of creating new technologies for the production of alpha-emitting radionuclides to solve the practical problems facing them and, in general, served the development of nuclear medicine in Russia and in the world," said Stepan Khamyanov, chief engineer of the Scientific and Production Complex of Isotopes and Radiopharmaceuticals of the State Research Center of the Russian Federation - FEI.

Global Ac-225 Production Volumes

The total production of Ac-225 in the world according to information for March 2023 is about 1.5 Ki/year.

Illustration: JSC "SSC RF - FEI"

2019: The supply of actinium-225 to the RNCRKT named after Academician A.M. Granov has begun.

Since 2019, the supply of actinium for the development of a domestic radiopharmaceutical drug (RFLP) has begun at the RNCRCT named after Academician A.M. Granov of the Ministry of Health of Russia.

2002: Technology developed to extract actinium-225 from long-held uranium-233

In 2002, JSC SSC RF - FEI developed a technology for the separation of actinium-225 from long-held uranium-233.